Literature DB >> 621283

Characterization of the immunochemical forms of calcitonin released by a medullary thyroid carcinoma in tissue culture.

D Goltzman, A S Tischler.   

Abstract

Immunoreactive calcitonin released by a medullary thyroid carcinoma in tissue culture has been found to exhibit heterogeneity when analyzed by gel chromatography and radioimmunoassay, in a pattern analogous to that seen in the circulation of the patient from whom the neoplasm was removed. To examine the cause of the heterogeneity, the immunoreactive material released by the tumor into tissue culture medium was further analyzed by gel electrophoresis in the presence of the protein denaturant 8 M urea, by gel chromatography after reduction and alkylation, by affinity chromatography on concanavalin A-agarose, and by bioassay in a renal adenylyl cyclase system of enhanced sensitivity. The results suggest that the larger immunochemical forms of calcitonin described in the circulation of patients with medullary thyroid carcinoma may be released directly from the neoplasm and need not derive from peripheral metabolism of the monomer. It could be demonstrated that a major proportion of the immunochemical enlargement is dependent upon intermolecular disulfide bridge formation whereas aggregation or non-convalent protein binding account for a smaller component of the heterogeneity. In view of the absence of binding of the immunoreactive material to the lectin agarose, carbohydrate side chains, at least of the alpha-d glucosyl variety, do not seem to contribute significantly to calcitonin enlargement. Additionally, the studies indicate that, at least by in vitro assay, the larger immunochemical forms of calcitonin, representing the majority of the immunoreactivity released by a medullary thyroid carcinoma, are biologically inactive.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 621283      PMCID: PMC372556          DOI: 10.1172/JCI108956

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  40 in total

1.  Immunochemical heterogeneity of calcitonin in plasma.

Authors:  L J Deftos; B A Roos; D Bronzert; J G Parthemore
Journal:  J Clin Endocrinol Metab       Date:  1975-03       Impact factor: 5.958

2.  Human calcitonin. Immunologic assay, cytologic localization and studies on medullary thyroid carcinoma.

Authors:  A H Tashjian; H J Wolfe; E F Voelkel
Journal:  Am J Med       Date:  1974-06       Impact factor: 4.965

3.  Evidence for a pro-calcitonin.

Authors:  B A Roos; K Okano; L J Deftos
Journal:  Biochem Biophys Res Commun       Date:  1974-10-08       Impact factor: 3.575

4.  Multiple immunoreactive forms of calcitonin in human plasma.

Authors:  F R Singer; J F Habener
Journal:  Biochem Biophys Res Commun       Date:  1974-11-27       Impact factor: 3.575

5.  Human calcitonin radioimmunoassay in normal and pathological conditions.

Authors:  G Heynen; P Franchimont
Journal:  Eur J Clin Invest       Date:  1974-06       Impact factor: 4.686

6.  Immunoreactive calcitonin in medullary carcinoma of the thyroid and in maternal and cord serum.

Authors:  N A Samaan; C S Hill; J R Beceiro; P N Schultz
Journal:  J Lab Clin Med       Date:  1973-05

7.  [Epithelioma of the thyroid secreting thyrocalcitonin].

Authors:  G Milhaud; M Tubiana; C Parmentier; G Coutris
Journal:  C R Acad Hebd Seances Acad Sci D       Date:  1968-02-05

8.  [Thyrocalcitonin-secreting carcinoid].

Authors:  G Milhaud; C Calmettes; J P Raymond; J Bignon; M S Moukhtar
Journal:  C R Acad Hebd Seances Acad Sci D       Date:  1970-05-04

9.  Effect of salmon calcitonin on renal excretion of adenosine 3', 5' monophosphate in man.

Authors:  R Ardaillou; R Isaac; M P Nivez; J M Kuhn; J L Cazor; J P Fillastre
Journal:  Horm Metab Res       Date:  1976-03       Impact factor: 2.936

10.  High molecular weight forms of adrenocorticotropic hormone are glycoproteins.

Authors:  B A Eipper; R E Mains; D Guenzi
Journal:  J Biol Chem       Date:  1976-07-10       Impact factor: 5.157

View more
  9 in total

1.  Effect of calcitonin deficiency on bone density and bone turnover in totally thyroidectomized patients.

Authors:  P Schneider; P Berger; K Kruse; W Börner
Journal:  J Endocrinol Invest       Date:  1991-12       Impact factor: 4.256

2.  Procalcitonin: a marker for the diagnosis and follow-up of patients with medullary thyroid carcinoma.

Authors:  Alicia Algeciras-Schimnich; Carol M Preissner; J Paul Theobald; Mary S Finseth; Stefan K G Grebe
Journal:  J Clin Endocrinol Metab       Date:  2008-12-16       Impact factor: 5.958

3.  Purification and partial characterization of high-molecular-weight forms of ectopic calcitonin from a human bronchial carcinoma cell line.

Authors:  J Lumsden; J Ham; M L Ellison
Journal:  Biochem J       Date:  1980-10-01       Impact factor: 3.857

Review 4.  Calcitonin: perspectives in current concepts.

Authors:  H J Wolfe
Journal:  J Endocrinol Invest       Date:  1982 Nov-Dec       Impact factor: 4.256

5.  Structural characterization of a high-molecular-mass form of calcitonin [procalcitonin-(60-116)-peptide] and its corresponding N-terminal flanking peptide [procalcitonin-(1-57)-peptide] in a human medullary thyroid carcinoma.

Authors:  J M Conlon; L Grimelius; L Thim
Journal:  Biochem J       Date:  1988-11-15       Impact factor: 3.857

6.  Tumour calcitonin. Interaction with specific calcitonin receptors.

Authors:  J Ham; M L Ellison; J Lumsden
Journal:  Biochem J       Date:  1980-09-15       Impact factor: 3.857

7.  Pronounced elevation in circulating calcitonin in critical care patients is related to the severity of illness and survival.

Authors:  L Lind; E Bucht; S Ljunghall
Journal:  Intensive Care Med       Date:  1995-01       Impact factor: 17.440

8.  Salmon and human calcitonin like material in lung cancer.

Authors:  C Gropp; W Luster; K Havemann
Journal:  Br J Cancer       Date:  1985-06       Impact factor: 7.640

9.  Procalcitonin as Marker of Recurrent Medullary Thyroid Carcinoma: A Systematic Review and Meta-Analysis.

Authors:  Pierpaolo Trimboli; Luca Giovanella
Journal:  Endocrinol Metab (Seoul)       Date:  2018-06
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.